__TypeId__: tech.gyri.marketingcloud.shared.emailcampaign.events.EmailCampaignAllFieldsUpdatedEvent
{"id":"67a0e5f0-7f8a-4053-a3e5-3b302390aecf","segmentIdList":[{"segmentId":"a3b4dba6-745f-4e55-8d5b-0e0c8c883ccc","order":1,"segmentInfo":{"id":"a3b4dba6-745f-4e55-8d5b-0e0c8c883ccc","name":"Customer UUID","description":"Customer UUID","operator":"OR","segmentLogicConditions":[{"value":"Chet90","attributeId":"eb5f266e-d1a1-42e9-85bc-0d94e58fb00d","operatorId":"10e220cf-61f7-461e-a686-901b71390c7f","attributeIdInfo":null,"operatorIdInfo":null}],"status":"ACTIVE","createdOn":1773038975000}}],"campaignTypeId":"dc1a1a5a-f76f-41ec-a01b-6c91b338ba1f","name":"Test 7673 ll","campaignGoalIds":["48d3d45e-8cfa-491a-aee8-107fc301cf3c"],"description":"Test 145","templateId":"0d40536f-9f39-4d9e-9574-67ed402dcdd0","subject":"Test 144","schedulerStatus":"SCHEDULED","schedulerStartDate":"13-06-2026","schedulerStartTime":"09:40","audienceCategoryId":"","timeZone":"Asia/Kolkata","emailConfigId":"ea9d6f77-b3e0-401c-b026-ce8f83ed715a","templateInlineDesign":"<!DOCTYPE html>\n<html>\n\n<head>\n <meta charset=\"UTF-8\">\n <title>Wockhardt Newsletter</title>\n</head>\n\n<body style=\"margin:0;padding:0;background:#f6f2fa;font-family:Arial,sans-serif;\">\n <div style=\"\n max-width:700px;\n margin:0 auto;\n position:relative;\n overflow:hidden;\n font-family:Arial, Helvetica, sans-serif;\n\">\n\n <!-- Full Page Background -->\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/834d0f6f-6fd2-4d90-80ef-26819a2f827f/ui/view?APP-Tenant-Id=gyri-demo\" alt=\"\" style=\"\n position:absolute;\n top:0;\n left:0;\n width:100%;\n height:118%;\n z-index:1;\n display:block;\n \">\n\n <!-- Content -->\n <div style=\"\n position:relative;\n z-index:2;\n padding:15px;\n \">\n\n <!-- CONTENT -->\n <div style=\"position:relative;z-index:2;padding:24px;\">\n <tr>\n <td style=\"padding:20px 30px;\">\n <table width=\"100%\">\n <tr>\n <td style=\" color:#7d2d91\">\n <strong>1st June 2026</strong>\n </td>\n\n <td align=\"right\">\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/def4dd58-9a3f-4abc-ade2-9530a470d9b4/ui/view?APP-Tenant-Id=gyri-demo\" width=\"120\">\n </td>\n </tr>\n </table>\n </td>\n </tr>\n\n <!-- HEADER -->\n <table width=\"100%\" cellpadding=\"0\" cellspacing=\"0\">\n <tr>\n\n <!-- LEFT TEXT -->\n <td width=\"68%\" valign=\"top\" style=\"padding:40px 20px 40px 0px;\">\n\n <p style=\"\n color:#7d2d91;\n font-size:14px;\n font-weight:bold;\n margin:0 0 16px;\n \">\n Dear Doctor,\n </p>\n\n <p style=\"\n font-size:14px;\n color:#222;\n line-height:22px;\n font-weight:bold;\n margin:0 0 14px;\n \">\n Today marks a historic moment for both India and Wockhardt,\n with the culmination of a journey that began more than two\n decades ago with a simple belief: that India could create\n antibiotic innovations capable of changing the course of\n global healthcare.\n </p>\n\n <p style=\"\n font-size:14px;\n color:#222;\n line-height:22px;\n font-weight:bold;\n margin:0 0 14px;\n \">\n <span style=\" color:#7d2d91\">\n The approval of ZAYNICH® (Zidebactam and Cefepime)\n by the US FDA and India's CDSCO is a milestone\n </span>\n that establishes India as a centre of R&D innovation and\n demonstrates that breakthrough science developed in India\n can meet the highest global standards of safety,\n efficacy and clinical excellence.\n </p>\n\n <p style=\"\n font-size:14px;\n color:#222;\n line-height:22px;\n font-weight:bold;\n margin:0;\n \">\n This milestone affirms\n <span style=\" color:#7d2d91\">\n Wockhardt R&D's capabilities\n to deliver globally recognised innovative antibiotic\n solutions\n </span>\n and signals a new chapter in Wockhardt's\n global ambition and scientific commitment.\n </p>\n\n </td>\n\n <!-- RIGHT BADGES -->\n <td width=\"32%\" valign=\"center\" align=\"center\">\n\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/ea360bb3-b812-48af-8d56-534638f726ab/ui/view?APP-Tenant-Id=gyri-demo\" alt=\"US FDA\" style=\"width:140px;display:block;margin:auto;\">\n <div style=\"\n display:inline-flex;\n align-items:center;\n background:#7c3aa1;\n color:#fff;\n padding:6px 10px;\n border-radius:25px;\n font-family:Arial,sans-serif;\n font-size:14px;\n font-weight:600;\n margin-top: 6px;\n \">\n <span style=\"margin-right:8px;\">\uD83D\uDCC5</span>\n May 27, 2026\n </div>\n <div style=\"height:14px;\"></div>\n\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/beaef2bc-36fa-4eb0-bf9f-ff642158095b/ui/view?APP-Tenant-Id=gyri-demo\" alt=\"CDSCO\" style=\"width:140px;display:block;margin:auto;\">\n <div style=\"\n display:inline-flex;\n align-items:center;\n background:#7c3aa1;\n color:#fff;\n padding:6px 10px;\n border-radius:25px;\n font-family:Arial,sans-serif;\n font-size:14px;\n font-weight:600;\n margin-top: 6px;\n \">\n <span style=\"margin-right:8px;\">\uD83D\uDCC5</span>\n May 30, 2026\n </div>\n </td>\n\n </tr>\n </table>\n\n <!-- SPACER -->\n <div style=\"height:28px;\"></div>\n\n <!-- SECTION 1 -->\n <table width=\"100%\" cellpadding=\"0\" cellspacing=\"0\">\n <tr>\n\n <td width=\"60\" valign=\"top\">\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/814791a9-2f7a-4482-a683-b40f5241441b/ui/view?APP-Tenant-Id=gyri-demo\" style=\"width:70px;\">\n </td>\n\n <td valign=\"top\">\n\n <p style=\"\n margin:0 0 0 10px;\n color:#333;\n font-size:14px;\n line-height:22px;\n font-weight:bold;\n \">\n This achievement comes at a critical time.\n Antimicrobial resistance (AMR) is among the world's\n greatest healthcare threats, contributing to more than\n one million deaths annually.\n </p>\n\n </td>\n\n </tr>\n </table>\n\n <div style=\"height:20px;\"></div>\n\n <!-- SECTION 2 -->\n <table width=\"100%\" cellpadding=\"0\" cellspacing=\"0\">\n <tr>\n\n <td width=\"60\" valign=\"top\">\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/af13489b-2bf9-4ca8-a7d7-3c9924531640/ui/view?APP-Tenant-Id=gyri-demo\" style=\"width:70px;\">\n </td>\n\n <td valign=\"top\">\n\n <p style=\"\n margin:0 0 0 10px;\n color:#333;\n font-size:14px;\n line-height:22px;\n font-weight:bold;\n \">\n Recognising this challenge early, Wockhardt committed\n itself to long-term antibiotic research. Our anti-infective\n programme earned Qualified Infectious Disease Product\n designation from the US FDA.\n </p>\n\n </td>\n\n </tr>\n </table>\n\n <div style=\"height:20px;\"></div>\n\n <!-- SECTION 3 -->\n <table width=\"100%\" cellpadding=\"0\" cellspacing=\"0\">\n <tr>\n\n <td width=\"60\" valign=\"top\">\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/823c992d-af8c-4991-97d5-c9e8a3c7d363/ui/view?APP-Tenant-Id=gyri-demo\" style=\"width:70px;\">\n </td>\n\n <td valign=\"top\">\n <p style=\"\n margin:0 0 0 10px;\n color:#333;\n font-size:14px;\n line-height:22px;\n font-weight:bold;\n \">\n ZAYNICH® combines Cefepime with Wockhardt’ s novel Zidebactam,\n a first-in-class beta-lactamase enhancer. This novel mechanism\n simultaneously targets multiple penicillin-binding proteins, providing\n bactericidal activity against the most challenging drug-resistant\n pathogens, including those that produce Metallo-Beta-Lactamases\n (MBLs) and serine Carbapenemese.\n </p>\n\n </td>\n\n </tr>\n </table>\n\n <div style=\"height:20px;\"></div>\n\n <!-- SECTION 4 -->\n <table width=\"100%\" cellpadding=\"0\" cellspacing=\"0\">\n <tr>\n\n <td width=\"60\" valign=\"top\">\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/42966a40-9d77-43f4-86de-b3eff41ec0cb/ui/view?APP-Tenant-Id=gyri-demo\" style=\"width:70px;\">\n\n </td>\n\n\n <td valign=\"top\">\n\n <p style=\"\n margin:0 0 0 10px;\n color:#333;\n font-size:14px;\n line-height:22px;\n font-weight:bold;\n \">\n ZAYNICH® has undergone extensive clinical trials conducted across 9\n countries and is supported by more than 200 scientific publications and\n presentations. In the pivotal Phase 3 ENHANCE-1 randomised,\n double-blind, multicentre trial (N=529), ZAYNICH® demonstrated superior\n combined clinical cure and microbiologic response versus meropenem at\n the test of cure (TOC) visit: 89.0% vs. 68.4%, representing a 20.6\n percentage point difference (95% CI: 12.3, 29.5).\n </p>\n\n </td>\n\n </tr>\n </table>\n\n <!-- PURPLE BOX -->\n <div style=\"\n margin-top:30px;\n background:#74298a;\n color:#fff;\n border-radius:10px;\n padding:18px;\n font-size:14px;\n line-height:24px;\n \">\n ZAYNICH® is already making a difference today. Through its compassionate-use\n programme, ZAYNICH® has helped save more than 85 lives across the United\n States, France, Malaysia, and India in cases where all other antibiotics had failed.\n As we expand access to ZAYNICH® across India and around the world, we do so with\n a profound sense of responsibility and optimism. The fight against antimicrobial\n resistance cannot be won by any one institution alone.\n It requires the collective efforts of physicians, healthcare organisations public health\n experts, policymakers and innovators\n </div>\n\n <!-- SPACING -->\n <div style=\"height:32px;\"></div>\n\n <!-- QUOTE + MESSAGE -->\n <table width=\"100%\" cellpadding=\"0\" cellspacing=\"0\">\n\n <tr>\n\n <td width=\"35%\" valign=\"top\">\n\n <div style=\"\n border:3px solid #74298a;\n border-radius:8px;\n padding:18px;\n \">\n\n <div style=\"\n color:#0a0a0a;\n font-size:28px;\n line-height:34px;\n font-style:italic;\n \">\n \"The future depends on what you do today\"\n </div>\n\n <div style=\"\n margin-top:12px;\n color:#74298a;\n font-size:12px;\n \">\n - Mahatma Gandhi\n </div>\n\n </div>\n\n </td>\n\n <td width=\"5%\"></td>\n\n <td width=\"60%\" valign=\"top\">\n\n <p style=\"\n margin-top:0;\n color:#333;\n font-size:14px;\n line-height:24px;\n font-weight:bold;\n \">\n On behalf of the entire Wockhardt family, I extend my\n deepest gratitude to everyone who believed in this\n vision and helped bring it to life, demonstrating that\n science guided by purpose and perseverance makes\n extraordinary outcomes possible.\n </p>\n\n <p style=\"\n color:#74298a;\n font-size:14px;\n font-weight:bold;\n line-height:24px;\n \">\n We look forward to partnering with you in protecting\n and saving lives in the years ahead.\n </p>\n\n </td>\n\n </tr>\n\n </table>\n\n <!-- SIGNATURE -->\n <div style=\"margin-top:35px;\">\n\n <div style=\"\n color:#333;\n font-size:14px;\n margin-bottom:10px;\n font-weight:bold;\n \">\n With gratitude and pride,\n </div>\n\n <img src=\"https://api-prod01.engagesphere360.com/mkc/api/v1/document/949ec7f8-9c56-400a-94a3-a28f022b7391/ui/view?APP-Tenant-Id=gyri-demo\" alt=\"Signature\" style=\"\n width:180px;\n display:block;\n \">\n\n <div style=\"\n margin-top:12px;\n color:#53276f;\n font-size:16px;\n font-weight:bold;\n \">\n Dr. Habil F. Khorakiwala\n </div>\n\n <div style=\"\n color:#666;\n font-size:13px;\n margin-top:4px;\n \">\n Founder Chairman, Wockhardt\n </div>\n\n </div>\n\n </div>\n\n </div>\n</body>\n\n</html>","departmentId":"42072c16-8b6a-4d9e-a1a9-f4d5b4335a58","lastUpdatedOn":1781180507617,"remoteAddress":"103.93.98.39","remoteHostName":"103.93.98.39","triggeredBy":"b4070763-4b27-4d79-9479-6529b4b1e341","version":1,"auditTrail":false,"tenantId":"gyri-demo"}
